1.83 USD
▲-0.01+7.02%
盘后 1.82 +6.43%
2026-08-03
市值
$258.25M
市盈率
—
EPS
-0.50
股息率
—
52 周区间
1.33 – 3.10
成交量
1.25M
Beta
0.04
目标价
8.25
52W 低 1.3352W 高 3.10
价格走势
公司简介
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metab...